Algorithme Pharma  
 
 

CRO & Biopharma Partnering to Optimize GO/NO GO Decisions in Phase l & lla Trials: Case Studies

 
 
 

Join us for a complimentary scientific webinar focusing on maximizing the Early Stage CRO & Biotech relationship. Involving a CRO early on when planning Phase 1 studies can facilitate attaining key clinical trial milestones and accelerate the GO/NO GO decision process.

This webinar will highlight case studies, presented from the sponsor viewpoint, which demonstrate early strategic CRO partnering advantages and how a timely relationship can optimize the drug development process for Biopharma companies.

Duration is one hour. There is no charge to attend.
Register now, places are limited.

 
DATE & TIME »

March 20th, 2013
11AM - 12PM EST

 
 
 

We look forward to welcoming you!

The Algorithme Pharma Team

 
 
  » SPEAKERS  
 
Dr. Marc Lefebvre

Dr. Marc Lefebvre, B. Pharm., M.Sc., Ph.D.
Vice-President, Scientific & Regulatory Affairs

Dr. Marc Lefebvre is the co-founder and the Vice-President, Scientific & Regulatory Affairs at Algorithme Pharma, a Contract Research Organization (CRO) involved in the conduct of Early Stage Clinical Trials. He leads scientific, regulatory and pharmacological decisions on every clinical trial conducted at the organization. His industry experience includes Phase I/II clinical trials at Schering Canada, Marion Merrell Dow Canada and Glaxo-Welcome.

He is very involved with the University of Montreal as an invited professor for lectures in pharmacology and pharmacokinetics. Over the years, he also participated in different industry related workshops and symposiums including the publication of several abstract and papers.

Dr. Patrick Colin

Dr. Patrick Colin,  B. Pharm., M.Sc., Ph.D.
Chief Development Officer, GIcare Pharma and President, PCC Inc.

Dr. Patrick Colin, is a seasoned drug development expert with more than 25 years experience in global pharmaceutical product development within large & mid-size pharmaceutical firms and biotechs, including the creation of new firms and their financing. He is the former VP of R&D with Axcan Pharma Inc., a successful Canadian pharmaceutical company specializing in gastroenterology and hepatology. Dr. Colin’s vast experience includes numerous therapeutic areas through to managing drug development programs which led to 15 regulatory approvals in Canada, the USA, Europe and Australia.

He is a full time Drug Development Consultant, offering a variety of scientific, regulatory and strategic services to the biopharmaceutical industry, both locally and internationally. In 2011, he became the co-founder and Chief Development Officer of Gicare Pharma, a new GI focused biotech, located in Montreal, Canada.

 
 
 

Algorithme Pharma
575, Armand-Frappier, Laval, QC Canada H7V 4B3

Contact us at contact@algopharm.com